cmAngio® vs AI-CVD
AI Verdict
Choose cmAngio® if…
Choose cmAngio® if your primary goal is to leverage existing mammography workflows to assess cardiovascular risk specifically in women. This tool is ideal for breast imaging centers or women's health clinics seeking to identify Breast Arterial Calcifications (BAC) on both FFDM and DBT exams, providing valuable insights into cardiovascular health without additional radiation or procedures.
View cmAngio® →Choose AI-CVD if…
Choose AI-CVD® if you aim to perform opportunistic, broad-spectrum cardiovascular and multisystem disease screening using existing chest and abdominal CT scans. This platform is best suited for radiology departments or cardiology practices looking to automate the detection of hidden health risks, including Coronary Artery Calcium (CAC) scoring, aortic calcifications, and cardiac chamber volumetry, without requiring new imaging or workflow disruption.
View AI-CVD →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
cmAngio®Tool A, cmAngiou00ae, explicitly highlights a quick and easy installation process (less than an hour) and compatibility with any DICOM-compliant viewer, directly addressing integration ease and user experience [2]. Clinical experience also suggests it significantly reduces flags and speeds up turnaround times, enhancing radiologist efficiency [15]. While Tool B emphasizes no workflow disruption, Tool A provides more specific details on practical usability features.
Clinical Value
AI-CVDTool B, AI-CVDu00ae, offers a broader and more comprehensive opportunistic screening for a wide range of cardiovascular and multisystem diseases using existing CT scans [3, 4, 6]. It provides numerous quantitative measurements for conditions like coronary artery calcium, heart failure, stroke, osteoporosis, liver steatosis, and diabetes, offering more expansive clinical utility compared to Tool A's specific focus on Breast Arterial Calcifications from mammograms [4, 5, 6, 17, 22].
Pricing & Value
cmAngio®Both tools require direct contact for pricing, indicating a lack of public transparency. However, Tool A, cmAngiou00ae, explicitly mentions potential 'limited-time offers for no-cost implementation and service' [14]. This suggests a more transparent approach to value proposition and could represent a significant cost advantage or lower barrier to entry for healthcare providers.
Enterprise Readiness
cmAngio®Both tools are FDA-cleared and cloud-based. However, Tool A, cmAngiou00ae, explicitly states it is 'Cybersecure and HIPAA-compliant' [2], providing a more definitive assurance regarding data security and regulatory compliance. Tool B uses 'likely, contact vendor' for HIPAA and BAA, making Tool A's claims more concrete for enterprise deployment.
Innovation
AI-CVDWhile cmAngio's AI application for BAC detection on mammograms is innovative for women's cardiovascular health, AI-CVD's broader approach to opportunistic screening across multiple systems from existing CT scans is more expansive [3, 4, 6, 17, 22]. Its ability to derive a wide array of quantitative measurements for various cardiovascular and multisystem diseases represents a more versatile and transformative innovation in leveraging existing imaging data for preventive medicine [4, 5, 6, 17].
Support & Docs
TieNeither the provided structured facts nor the web search results offer sufficient specific details regarding the depth, accessibility, or responsiveness of customer support, training programs, or comprehensive documentation for either tool. While an 'Operator's Manual' is mentioned for Tool A [2] and a 'Knowledge Center' for Tool B [23], there's no clear differentiator to pick a winner.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | cmAngio® | AI-CVD |
|---|---|---|
| Product Name | cmAngiou00ae | AI-CVDu00ae |
| Company | CureMetrix | HeartLung Corporation |
| Primary Purpose | FDA-cleared AI software for detecting Breast Arterial Calcifications (BAC) on mammograms, providing insights into cardiovascular health and aiding early risk assessment. | FDA-cleared, AI-powered quantitative imaging platform that performs opportunistic screening for cardiovascular and multisystem diseases using existing CT scans, enabling early detection of hidden health risks. |
| Input Imaging Modality | Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) exams | Existing chest and abdominal CT scans |
| Key Detections/Measurements | AI-based detection of Breast Arterial Calcifications (BAC), visualization of BAC location on a scorecard | Coronary Artery Calcium (CAC) scoring, Aortic wall/valve/mitral valve calcium analysis, Cardiac chamber volumetry, Epicardial fat volumetry, Aorta and pulmonary artery sizing |
| Specialties | Cardiology, Obstetrics & Gynecology, Radiology | Cardiology, Pulmonology, Radiology |
Videos
Demos, reviews, and walkthroughs featuring cmAngio® and AI-CVD.